TGA Market Actions as a Quality System Stress Test

Lessons from the March 2026 TRUE METRIX device correction

In March 2026, the Therapeutic Goods Administration (TGA) published a market action for the TRUE METRIX® Blood Glucose Monitoring Systems, describing a product correction prompted by gaps in the clarity of the Instructions for Use (IFU). On the surface, the issue related to a single device error code. In practice, however, the action provides a useful stress test of how well a sponsor’s quality management system (QMS) integrates labelling control, post‑market surveillance (PMS), risk management and corrective and preventive action (CAPA).

For sponsors and manufacturers, particularly those operating across multiple jurisdictions, this case reinforces a familiar regulatory truth: many significant market actions do not arise from catastrophic device failures, but from cumulative weaknesses in how products are described, understood and used in real‑world settings. This blog explores the TRUE METRIX correction as a practical case study and draws broader lessons for strengthening QMS resilience.

Market actions vs recalls vs corrections: why wording matters

Under the TGA’s current recall framework, ‘market action’ is the umbrella term used to describe actions taken to address problems or potential concerns with therapeutic goods supplied in Australia. Market actions include recalls, product alerts and product corrections. The distinction between these action types is critical, as it determines the scope of response, the urgency of communication, and the expectations placed on sponsors.

A product correction, such as the TRUE METRIX action, is generally used where the product can remain in supply and the identified issue can be mitigated through updates to information, labelling or instructions. While this may appear less severe than a recall, it still represents a formal regulatory action and requires disciplined execution. From a QMS perspective, selecting and justifying the correct action type is itself a test of risk assessment capability and regulatory judgement. Poorly chosen terminology can result in regulatory challenge, misaligned communications, or reputational harm.

Case study summary: instruction clarity and patient risk

The March 2026 market action for TRUE METRIX® Blood Glucose Monitoring Systems related to how the IFU described the E‑5 error code. The system may display this code when blood glucose levels are extremely high or when a test strip error occurs. The TGA noted that the existing instructions did not clearly advise users to seek urgent medical attention when symptoms of high blood glucose were present.

The risk identified was not a failure of the device to detect high glucose levels, but a risk of delayed treatment due to ambiguous or insufficient instructions. In high‑risk clinical scenarios, even short delays can have serious consequences. The correction therefore focused on updating the IFU to clearly explain what actions users should take when the E‑5 error code appears, particularly in the presence of symptoms.

This distinction is important. Many sponsors focus heavily on hardware and software performance, but regulators increasingly scrutinise whether the information provided supports safe and effective use in practice. Usability and comprehension are integral components of device safety.

What this means for your QMS: labelling, PMS and risk management

From a QMS perspective, the TRUE METRIX case illustrates how documentation‑related issues can escalate into formal market actions. Robust labelling control processes should ensure that IFUs are not only technically correct, but also clear, unambiguous and aligned with foreseeable user behaviour. This includes considering health literacy, stress conditions and atypical but plausible use scenarios.

Post‑market surveillance plays a critical role in identifying when labelling or instructions are not performing as intended. Complaint handling systems that focus narrowly on device malfunctions may miss important signals related to user confusion or delayed response. Effective PMS processes typically include:

• Trend analysis of complaints and enquiries that reference misunderstanding or uncertainty
• Linkage between complaints, incident reports and risk management files
• Regular review of IFUs and labelling against emerging post‑market data
• Escalation pathways for potential use‑error risks, even in the absence of device failure

Risk management files should explicitly address use error and information‑related hazards, and be treated as living documents. When post‑market data indicates that instructions are not driving the intended user behaviour, reassessment is warranted. This is an area where many organisations underestimate regulatory expectations.

CAPA depth and effectiveness: moving beyond document updates

Implementing a CAPA in response to a market action is not limited to correcting the immediate issue. Regulators expect sponsors to understand and address the root causes that allowed the issue to arise. In the context of the TRUE METRIX correction, this extends beyond revising IFU wording.

Good practice CAPA investigations typically explore questions such as:

• Why was the original instruction considered adequate during pre‑market review?
• What usability testing or review processes were in place, and what were their limitations?
• Were post‑market signals available earlier, and if so, why were they not escalated?
• Are similar instruction patterns present in other products within the portfolio?

Demonstrating CAPA effectiveness is often where sponsors encounter difficulty. Updating a document is rarely sufficient on its own. Effectiveness measures may include targeted complaint trend reviews, follow‑up monitoring of related enquiries, or internal audits focused on labelling governance. Where usability issues are identified, sponsors may also consider additional user testing or expert review as part of preventive action. Clear documentation of these activities is essential to evidence that the risk of recurrence has been reduced.

Usability engineering: the often‑underestimated control

Usability engineering is a recurring theme in many post‑market actions, even when not explicitly labelled as such. Instructions that appear clear in isolation may be interpreted differently by users under stress, fatigue or clinical urgency. The TRUE METRIX case reinforces the importance of considering context of use throughout the product lifecycle.

Typical usability‑related enhancements sponsors adopt include:

• structured readability reviews,
• involvement of clinical or consumer representatives in IFU updates,
• and formal linkage between usability findings and risk controls.

While not all these activities are mandated, they are increasingly viewed as indicators of a mature and proactive QMS.

For further analysis read: The Cost of Overlooking Usability.

Mock recall drills and communication preparedness

Even where a product correction is anticipated rather than a recall, preparedness remains critical. Mock recall or market action drills are a practical way to test whether decision‑making pathways, escalation processes and communication tools function as intended.

Communication packs prepared in advance for healthcare professionals and consumers can significantly reduce response time and error under pressure. These packs typically include pre‑approved messaging frameworks, contact pathways and internal roles and responsibilities. Importantly, they also support consistency across jurisdictions and stakeholder groups.

Global alignment and linked field safety notices

The TRUE METRIX correction also highlights the challenge of global alignment. Where a device is supplied internationally, sponsors must coordinate field safety notices, labelling updates and regulatory notifications across jurisdictions. Differences in timing or messaging can create confusion and attract additional regulatory scrutiny.

Strong global governance arrangements, including clear agreements between manufacturers and sponsors, are essential to manage these complexities. While regulators do not prescribe how this alignment must be achieved, inconsistencies are often viewed as a symptom of weak lifecycle oversight.

Practical tools to strengthen system resilience

Organisations use practical tools to support consistent, risk‑based decision‑making during market actions. These may include:

• decision trees to guide action classification,
• communication checklists to ensure completeness,
• and CAPA trackers that integrate effectiveness monitoring.

When embedded within the QMS, these tools can transform a regulatory challenge into an opportunity for continuous improvement. They also align well with broader quality maturity initiatives.

For further reading, see PharmOut’s blog on sponsor responsibilities for TGA product recalls. These resources complement the lessons from the TRUE METRIX case and provide practical guidance for sponsors seeking to enhance QMS robustness.

PharmOut Services & Training

PharmOut supports sponsors and manufacturers to strengthen quality system resilience across post‑market surveillance, labelling governance, risk management and CAPA.
Our consultants provide targeted gap assessments, mock recall and market action drills, and pragmatic remediation support aligned to TGA and global expectations.
We also deliver focused training on usability, PMS and market action readiness to help organisations move beyond document updates and embed sustainable, risk‑based practices.

Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.

Frequently Asked Questions (FAQ)